Regulatory Frameworks for Strengthening Pharmaceutical Supply Chain Security: A Comparative Analysis of EU-FMD and US-DSCSA
Abstract
False and counterfeit drugs are a significant worldwide medical danger especially in low and middle incomes where up to 1 out of 10 Medicines can be of inferior quality. Drug safety is also becoming hard to ensure through increased globalization and complexity of supply chains. Laws such as EU-FMD or US-DSCSA help to solve such problems by implementing the system of serialization, verifying, and tracing. At the same time, the centralized verification clarifies the concept of FMD, whereas DSCSA dwells upon end-to-end track-and-trace mechanisms. All these structures contribute to transparency and allow avoiding false medicines penetrating into the supply chain.
Conclusion: EU-FMD and US-DSCSA offer huge improvements in the supply chain security of the pharmaceutical; this is achieved by serialization, traceability, and verification systems. Even though their methods are not the same, both frameworks are successful in ensuring a decrease in the chances of falsified medicines. Ongoing technology innovation and harmonization of regulations across the globe are indispensable towards improvement in the future.
Downloads
References
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1429872/full/
2. World Health Organization. Poor and counterfeited medical products [Internet]. Geneva: WHO; 2017 [cited 2026 Mar 22]. Available from:
https://www.who.int/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified/
3. World Health Organization. Substandard and falsified medical products [Internet]. Geneva: WHO; 2018 [cited 2026 Mar 22]. Available from:
https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products/
4. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. The prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries. JAMA Netw Open [Internet]. 2018 [cited 2026 Jan 28];1(4):e181662. Available from: https://jamanetwork.com/
5. Salami RK, Valente de Almeida S, Gheorghe A, Njenga S, Silva W, Hauck K. Health, economic, and social impact of substandard and falsified medicines in low- and middle-income countries: a systematic review of methodological approaches. Am J Trop Med Hyg [Internet]. 2023 [cited 2026 Jan 28];108(1):1–17. Available from:
https://doi.org/10.4269/ajtmh.22-0525
6. Mackey TK, Nayyar G. Digital menace: a survey of international health, patient safety, and computer security risks of rogue online pharmacies. Br Med Bull [Internet]. 2016 [cited 2026 Jan 28];118(1):110–126. Available from:
https://doi.org/10.1093/bmb/ldw016
7. European Medicines Agency. Falsified Medicines Directive (FMD) [Internet]. EU: EMA; 2011 [cited 2026 Jan 28]. Available from:
https://www.ema.europa.eu/
8. U.S. Food and Drug Administration. Drug Supply Chain Security Act (DSCSA) [Internet]. US: FDA; 2013 [cited 2026 Jan 28]. Available from:
https://www.fda.gov/
9. Le P, Grund L, Marwa J, Ojo W, Otts J Jr, Arab F. Fighting substandard and counterfeit pharmaceuticals through pharmaceutical supply chain security: Drug Supply Chain Security Act (DSCSA) of 2013. Innov Pharm [Internet]. 2018 [cited 2026 Jan 28];9(2):1–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438546/
10. United States Congress. Drug Quality and Security Act (H.R. 3204) [Internet].US:congress.gov 2013 [cited 2026 Jan 28]. Available from:
https://www.congress.gov/
11. United States Pharmacopeia (USP). Drug Supply Chain Security Act (DSCSA): summary [Internet].US; USP; 2014 [cited 2026 Jan 28]. Available from:
https://www.usp.org/sites/default/files/usp/document/supply-chain/apec-toolkit/country-regional-guidelines/United%20States%20of%20AmericaDrug%20Supply%20Chain%20Security%20Act%20SummaryFood%20and%20Drug%20Administration.pdf
12. U.S. Food and Drug Administration. Product identifiers under DSCSA: questions and answers [Internet]. US FDA; 2021 [cited 2026 Jan 28]. Available from: https://www.fda.gov/media/116304/download
13. EMMA International. The Drug Supply Chain Security Act T3 data and DSCSA [Internet]. US:EMMA International 2024 Nov 6 [cited 2026 Jan 29]. Available from:
https://emmainternational.com/t3-data-and-the-drug-supply-chain-security-act-dscsa/
14. U.S. Food and Drug Administration. Enhanced drug distribution security under DSCSA: industry guidance [Internet]. US:FDA; 2023 [cited 2026 Jan 29]. Available from: https://www.fda.gov/media/117950/download
15. U.S. Food and Drug Administration. Suspect and illegitimate product definitions under DSCSA [Internet].US:FDA; 2021 [cited 2026 Jan 29]. Available from: https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/FDA/DSCSA-Definition-of-Suspect-and-Illegitmate-Product-guidance-%281%29.pdf
16. TrackTraceRx. OCI and authorized trading partners: a DSCSA requirement [Internet]. TrackTraceRx; 2021 [cited 2026 Jan 29]. Available from:
https://blog.tracktracerx.com/oci-and-authorised-trading-partners-a-dscsa-requirement
17. TraceLink. DSCSA timeline: what you need to know [Internet]. TraceLink; 2024 [cited 2026 Jan 30]. Available from:
https://www.tracelink.com/dscsa-timeline-what-you-need-know
18. Sarkar S. Digital traceability of pharmaceutical drugs in supply chain. [Internet]. ResearchGate;2022 [cited 2026 Jan 30];10(2):39–44. Available from:
https://www.researchgate.net/
19. Sundavadra R. Verification router services (VRS) in DSCSA compliance [Internet]. Jekson Vision 2024 Jun 25 [cited 2026 Jan 31]. Available from:
https://jeksonvision.com/the-role-of-verification-router-services-vrs-in-the-compliance-of-dscsa/
20. U.S. Food and Drug Administration. Interoperable exchange of information for drug tracing [Internet].US FDA; 2023 [cited 2026 Jan 30]. Available from:
https://www.fda.gov/media/171796/download
21. Enhance pharmaceutical supply chain through blockchain in internet of things. Internet Things J [Internet]. 2024 [cited 2026 Jan 30];26:101215.
22. Roy A, Mohapatra A, Sharwan C, Kumar A, Kumar S, Maholay A, et al. Pharmaceutical supply chain management artificial intelligence: a systematic review. World J Biol Pharm Health Sci [Internet]. 2025 [cited 2026 Jan 29];21(1):204–213. Available from:
https://doi.org/10.30574/wjbphs.2025.21.1.1088
23. Le P, Grund L, Marwa J, Ojo W, Otts J Jr, Arab F. Counterfeiting or low-quality medicines: combating with DSCSA. Innov Pharm [Internet]. 2018 [cited 2026 Jan 29];9(2):1–11. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438546/
24. Brechtelsbacher ED, Pennell B, Durham M, Hertig JB, Weber RJ. Analysis of Drug Supply Chain Security Act. Hosp Pharm [Internet]. 2016 [cited 2026 Jan 29];51(6):493–500. Available from:
https://pubmed.ncbi.nlm.nih.gov/27354753/
25. National Community Pharmacists Association. Drug Supply Chain Security Act: what pharmacists should know [Internet]. US:NCPA; 2020 Sep [cited 2026 Jan 29]. Available from: https://ncpa.org/sites/default/files/2020-09/hamacher-dscsa-slides.pdf
26. Smith G, Smith JA, Brindley DA. The falsified medicines directive: the way to secure supply chain. J Generic Med [Internet]. 2014 [cited 2026 Jan 29];11(3-4):169–172. Available from:
https://doi.org/10.1177/1741134315588986
27. Krähenbühl C. Delegated regulation EU-FMD safety features. Eur Ind Pharm [Internet]. 2016 [cited 2026 Jan 30];(28):4–. Available from:
https://farmaceitubiedriba.lv/uploads/files/eipg28complete.pdf
28. European Medicines Verification Organisation. European Medicines Verification System explained [Internet]. EU:EMVO; 2023 Jun 16 [cited 2026 Jan 30]. Available from:
https://emvo-medicines.eu/wp-content/uploads/The-European-Medicines-Verification-System-Explained.pdf
29. Systech. EU Falsified Medicines Directive infographic [Internet].; 2018 Mar [cited 2026 Feb 15]. Available from:
https://health.ec.europa.eu/medicinal-products/falsified-medicines_en/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
